The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.
 
Roy S. Herbst
Honoraria - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; NovaRX; pfizer
Consulting or Advisory Role - Biothera; DiaTech Oncology; Endocyte; Kolltan Pharmaceuticals; N-of-One
Research Funding - Genentech/Roche
 
Paul Baas
Honoraria - AstraZeneca; Verastem
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Jose Luis Perez-Gracia
Research Funding - Merck
 
Enriqueta Felip
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Roche
 
Dong-Wan Kim
No Relationships to Disclose
 
Ji-Youn Han
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer
Consulting or Advisory Role - Novartis
Speakers' Bureau - AstraZeneca; Roche
Research Funding - AstraZeneca; Boehringer Ingelheim; Roche
 
Julian R. Molina
No Relationships to Disclose
 
Joo-Hang Kim
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Roche (Inst)
 
Catherine Dubos Arvis
No Relationships to Disclose
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Research Funding - AstraZeneca (Inst)
 
Margarita Majem
No Relationships to Disclose
 
Mary J. Fidler
No Relationships to Disclose
 
Veerle Surmont
No Relationships to Disclose
 
Gilberto Castro
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Eurofarma; Pfizer; Teva
Speakers' Bureau - AstraZeneca; Bayer; Eurofarma; Lilly; Merck Serono; Novartis; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Boehringer Ingelheim; Eurofarma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
 
Marcelo Garrido
No Relationships to Disclose
 
Yue Shentu
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Marisa Dolled-Filhart
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Ellie Im
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Edward B. Garon
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)